The University of Virginia Cancer Center is conducting a clinical research study for adults ages 18 and over who are receiving treatment with cemiplimab or will soon start that treatment for advanced Cutaneous Squamous Cell Carcinoma (CSCC). The purpose of this research study is to understand the long-term effectiveness and safety of this drug in patients diagnosed with advanced CSCC.
Participation will last for up to 3 years. This study will follow your standard care and you will be asked to complete questionnaires throughout the duration of your participation.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT03836105